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ABSTRACT: The global prevalence of antibacterial resistance requires new antibacterial drugs with novel chemical scaﬀolds
and modes of action. It is also vital to design compounds with optimal physicochemical properties to permeate the bacterial cell
envelope. We described an approach of combining and integrating whole cell screening and metabolomics into early
antibacterial drug discovery using a library of small polar compounds. Whole cell screening of a diverse library of small polar
compounds against Staphylococcus aureus gave compound 2. Hit expansion was carried out to determine structure−activity
relationships. A selection of compounds from this series, together with other screened active compounds, was subjected to an
initial metabolomics study to provide a metabolic ﬁngerprint of the mode of action. It was found that compound 2 and its
analogues have a diﬀerent mode of action from some of the known antibacterial compounds tested. This early study highlighted
the potential of whole cell screening and metabolomics in early antibacterial drug discovery. Future works will require
improving potency and performing orthogonal studies to conﬁrm the modes of action.
■ INTRODUCTION
Antibacterial resistance, an issue under the umbrella term of
antimicrobial resistance (AMR), is becoming a major global
public health issue, aﬀecting both developed and developing
countries alike, although the impact in low and middle income
countries is disproportionately high.1−3 It has been estimated
that the global death toll associated with AMR could rise to 10
million and the cumulative economic cost to U.S. $100 trillion
by the year 2050 if AMR is not tackled urgently.3
Maintaining a healthy pipeline of new antibiotics is a key
strategy in combating AMR as bacterial resistance against
antibiotics is inevitable. An evaluation of the antibiotic pipeline
by the Pew Charitable Trust4 in September 2017 found that
there were 48 antibiotics in various phases in clinical
development. Despite these seemingly healthy numbers,
there are several caveats to this observation. First, there is
the risk of attrition in each phase of the clinical development of
antibiotics.5 Second, it was observed that most of the
antibiotics in the pipeline were iterations of some of the
major classes of antibiotics such as β-lactams, quinolones,
tetracyclines, and oxazolidinones. This strategy, while main-
taining a stream of new antibiotics, may suﬀer from the impact
of cross-resistance, in which resistance against one antibiotic
confers cross-resistance to other antibiotics of similar class,
either through mutation of the molecular target or some
common means of eﬄux or drug inactivation (e.g., β-
lactamases).
As such, it is vital to maintain a healthy pipeline of
antibiotics with either new modes of action or new chemical
scaﬀolds. There have been a very few new classes of antibiotic
uncovered since the golden age of antibiotic discovery (in the
1950s and 1960s),6 and the introduction of new classes of
antibiotics post-2000 (such as oxazolidinones, lipopeptides,
and mutilins) can be traced to their discovery before 1990.7
A key issue in the development of new antibiotics is
obtaining suﬃcient compound levels in cells, due to restricted
permeation of the bacterial cell envelope and ejection of
compounds through eﬄux pumps. The physicochemical
properties of compounds play a role in compound uptake.
The wealth of discussions8−12 on the physicochemical
properties of antibiotics and the comparison to other
nonantibiotics highlights the challenges of designing an
antibiotic with favorable physicochemical properties. The
precise physicochemical properties required for cell entry are
poorly understood. However, analysis suggests that antibacte-
rial compounds tend to be more polar than other drugs,10,12
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with compounds acting against Gram-negative bacteria tending
to be more polar/charged than those acting against Gram-
positive bacteria. As such, the choice of libraries for screening
bacteria is crucial to enhance the odds of ﬁnding hit
compounds with the appropriate antibacterial physicochemical
properties.
Current antibiotics target a limited set of enzymes or RNA
structures within key bacterial cellular processes, such as cell
wall biosynthesis, protein biosynthesis, and DNA biosynthesis.
Although these targets are validated, there should be a search
for other targets to treat bacteria resistant to current
antibiotics.
There are two main routes to drug discovery, target-based
and whole cell (phenotypic) approaches. Target-based
discovery is hindered by the challenges of compound
uptake/eﬄux, which means that compounds active in an
enzyme assay are not necessarily active against intact bacteria.
Further there is a risk that compounds that inhibit a single
target can be subject to high rates of resistance. Whole cell
approaches can also suﬀer from low hit rates due to compound
uptake/eﬄux issues; however, compounds that are active hit
essential targets and are able to accumulate to suﬃcient levels
at those molecular targets. Whole cell hit discovery requires
some degree of target deconvolution to ensure that whole cell
actives are targeting a novel and/or progressible target.
Knowledge of the binding mode of the lead in the protein is
also valuable for compound optimization and to overcome
issues such as poor pharmacokinetics.
Whole cell and target-based drug discovery processes are
complementary and can be merged into a hybrid model
(Figure 1). In this hybrid model, a library of compounds is
screened for whole cell activity. Hits from the screen are then
expanded to give various analogues to probe for any indicative
structure−activity relationship (SAR). Target deconvolution
can then be used to identify the molecular target. If the target
is suitable for development, target-based approaches can be
used in optimization and scaﬀold hoping. This approach has
the advantage of starting with compounds that are cell
penetrant and which give rise to the desired whole cell
response. The identiﬁed molecular targets possess a higher
degree of validation, as it has been demonstrated that a
druglike compound acting against this molecular target can
have a desired whole cell eﬀect on the bacteria.
We decided to screen against intact whole bacteria with a
diverse library of small polar compounds,10 which should
address the physicochemical properties to some extent and
being low molecular weight should cover a wide range of
chemical space as well.13,14 Furthermore, small polar fragment-
like molecules would facilitate optimization toward lead-like
molecules through the process of adding complexity.15
We decided to apply whole cell metabolomics as a way to
compare modes of action, to be able to identify compounds
that have a novel mechanism of action. Metabolomics can be
described as a comprehensive bioanalytical technique to
characterize and quantify metabolites of a biological system.16
Metabolites reﬂect the biochemical status of the biological
system. Since biochemical changes in a biological system lead
directly to changes in its whole cell response, it follows that
metabolomics can facilitate the understanding of the
genotype−phenotype link, as changes in metabolite levels
can be ascribed to changes in protein activity, which is linked
to genes as well as to environmental status, where precursor
metabolites are acquired by the cell. As such, the whole cell
response upon exposure to an antibacterial compound is a
function of the change in the metabolites. In some cases, this
can be deconvoluted to reveal aﬀected metabolic pathways and
individual target enzymes. This should provide a ﬁngerprint to
allow comparison of the modes of action of diﬀerent
compounds and potentially, in some cases, ultimately the
protein target. Some examples illustrate the use of metab-
olomics in this scenario.17−21
In this paper, we aim to describe the experience of using our
in-house small, fragment-like polar compound library as the
starting point in early antibacterial drug discovery. First, we
aim to see if low-molecular-weight “fragment-like” compounds
are a viable starting point for a drug discovery program and
second can we use metabolomic ﬁngerprints at this early stage
of the discovery process to compare modes of action. We will
present some early results, alongside thoughts and challenges
that arose during the process.
■ RESULTS AND DISCUSSION
Whole Cell Screening of In-house Library. An in-house
library of small, fragment-like polar molecules comprising of
almost 1300 compounds has been described in detail by Ray et
al.22 The library consisted of a diverse set of small molecules,
with physicochemical properties with low molecular weight
[heavy atom count (HAC) 5−18]; low lipophilicity (logD ≤
2.5 and log P ≤ 2.5), and aromatic rings ≤3 (these represent
the upper limits; the median values are much lower). These
physicochemical properties (low molecular weight and high
polarity) should increase the chances of entry into the
bacteria.8 Further, the low molecular weight means that it is
possible to cover a similar chemical space to libraries with
much larger numbers of leadlike or druglike compounds. The
library was curated to remove known structural alerts
(toxicophores, reactives, and pan-assay interference com-
pounds).22 The library was mainly composed of commercially
obtained fragments but also contained some proprietary
compounds. The whole cell assay was based on measuring
the turbidity of bacterial culture (as OD600nm) as a proxy of
growth. The screening was performed using 384-well plates to
enable high-throughput screening. As an example of Gram-
Figure 1. Steps involved in the hybrid whole cell/target-based drug
discovery.
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positive bacteria, Staphylococcus aureus RN4220, which was
used in previous in-house screenings, was utilized in this whole
cell assay. Compounds were initially screened at a single
concentration of 600 μM to reﬂect the low molecular weight of
these small fragment-like molecules.
From the single-point whole cell assay, 23 compounds were
returned as hits, deﬁned as having inhibitory activity at three
robust standard deviations from the median. To remove false
positives from the set of hits, a 10-point dose−response assay,
with the top concentration of 600 μM, was performed at the
whole cell level to seek any dose-dependent inhibitory activity
and to estimate the potency of these hits. Of the 23 hits
forwarded into the dose−response assay, two compounds, 1
and 2 (Figure 2), gave clear dose−response curves. Given their
small size, they had a relatively low potency [pEC50 less than 4,
where pEC50 = −log10(EC50)], which is not unexpected.
However, the ligand eﬃciencies (LE − determined as 1.37 ×
pEC50/heavy atom count) of the key hits were very promising,
0.30 and 0.35. By analogy with fragment-based drug discovery
processes, the small size allows scope for optimization, while
retaining ligand eﬃciency.
Compound 1 has been described in the literature as EX-527,
a SIRT1 inhibitor.23,24 Literature investigation revealed
compound 2 to be a ligand of the adenosine A2A receptor
discovered using fragment-based drug discovery.25,26 It was
also described as a noncompetitive inhibitor of the human
divalent metal transporter DMT1/SLC1 1A2, with the Ki of
approximately 20 μM.27 Interestingly, the pyrazolylpyrimidine
scaﬀold of 2 was described as having fungicidal activity.28,29
Additionally, 2 was described to be active against Mycobacte-
rium tuberculosis.30
Hit expansion of 2 was carried out, as 2 has lower molecular
weight and lipophilicity than 1 and a greater chemical
tractability, thus allowing greater complexity to be added
during the hit expansion process.
Resynthesis of 2 and Analogues. Compound 2 is a
pyrazolylpyrimidine. The distribution of various tautomeric
forms (pyrimidinone and hydroxypyrimidine) has been
discussed31 using various theoretical methods, albeit in the
gaseous phase. A computational study on complexes of 4-
hydroxypyrimidine with water suggested that the pyrimidinone
(4-oxopyrimidine) tautomeric form predominates over the 4-
hydroxypyrimidine tautomeric form at a 3:1 ratio at room
temperature (rt).32 Nevertheless, the hydroxypyrimidine
representation will be used throughout this paper for
consistency purposes and to aid visual comparison among
the analogues synthesized.
A key early goal of the project was to validate the series and
to try and increase its activity. The structure of 2 was amenable
to derivatization, to probe the eﬀect of various substituents at
diﬀerent locations on the scaﬀold, to increase potency (Figure
3). The choice of substituents for such a study was designed in
Figure 2. Dose−response curves of 1 and 2, together with the corresponding structures and potency described as pEC50.
Figure 3. Possible strategies in generating analogues of 2.
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a way that a simple change in the substituent can lead to
changes in physicochemical properties such as lipophilicity,
hydrogen bond donor and acceptor count, which will then
impact compound activity. Various synthetic routes were
generated to fulﬁll the various strategies highlighted in Figure
3.
Scheme 1. Synthesis of 2 and Analogues from 2,4-Dichloropyrimidine Derivativesa
aReagent and conditions: (a) 3,5-dimethylpyrazole, dioxane, microwave (MW) 150 °C, 3 h, 24−35%; (b) 1 M NaOH (aq), tetrahydrofuran
(THF), MW 150 °C, 0.5 h, 68−90%; (c) appropriate benzyl alcohol, Cs2CO3, MeCN, reﬂux, overnight, 36−79%; (d) 1:1 triﬂuoroacetic acid
(TFA)−dichloromethane (DCM), rt, 1 h, 72%; (e) MeI, K2CO3, dimethylformamide (DMF), reﬂux, overnight, 75%.
Scheme 2. Comparison of the Calculated Regio-isomeric Ratio of the Synthesis of 3 and 3b by Inclusion of the Basea
aCalculated ratio was based on NMR integration.
Scheme 3. Synthesis of Analogues of 2 from 2-Chloropyrimidine Derivativesa
aReagent and conditions: (a) 3,5-dimethylpyrazole, KOH, 18-crown-6, acetonitrile, room temperature, 1 day, 41−70%; or MW (80 °C, 15 min for
13; 120 °C, 30 min for 14), 32−47%; or for 17: 3,5-dimethylpyrazole, Cs2CO3, dioxane, MW 150 °C, 3 h, 64%; (b) LiCl, DMF, MW 160 °C, 30
min (3 h for 21), 24−97%; (c) LiOH−THF, rt, overnight, 87%; (d) NH3 (for 23) or MeNH2 (for 24) or Me2NH (for 25), MeOH, rt, overnight,
99−100%; (e) Burgess reagent, THF, rt, overnight, 93%.
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First, the pyrazolylpyrimidine compounds were derived by
reacting the pyrazole of interest with the appropriate
pyrimidines. Substituted 2,4-dichloropyrimidines were used
in the initial synthesis to generate the hit compound 2 and
other analogues via the 4-chloro intermediate (for example, 3
and 4) (Scheme 1).
The ﬁrst step in Scheme 1 suﬀered from regio-isomerism, in
which the displacement by the pyrazole derivative could occur
at either the 2-position or the 4-position of the pyrimidine ring.
Using the reaction to generate 3 as an example, it was
interesting to note that the formation of the desired regio-
isomer 3 was favored and enhanced without the presence of a
base (Scheme 2). However, the isolated yield was compro-
mised by the diﬃculty in separating both regio-isomers. The
structure of these regio-isomers was distinguished by perform-
ing 1H NMR experiments, in particular, nuclear Overhauser
enhancement spectroscopy (Figures S1−S3).
Initially, it was envisaged that the synthesis of the hit
compound 2 was carried out via the 4-methoxybenzyl ether
derivative 5 through a TFA-mediated deprotection reaction.
However, it transpired that direct hydroxylation of the 4-chloro
derivatives (3 and 4) was also possible via microwave-assisted
reaction with THF−NaOH solution, thus saving an additional
step in generating analogues of 2. Other benzyl ether
derivatives 6−9 were generated, thus increasing the diversity
of analogues. Additionally, the hit compound 2 was further
methylated to give the N-methyl product 11.
This synthetic scheme was extended to include 2-
chloropyrimdine derivatives as precursors to other analogues
with various substitutions on the 4- and 6-positions of the
pyrimidine core (Scheme 3). For example, the methoxy
derivatives 14−16 were demethylated to provide analogues
19−22.
The methyl ester analogue 17 provided another attractive
starting point for rapid hit expansion as it could be readily
derivatized. Hydrolysis provided the free acid 18, while
displacement with simple amines provided various amides
23−25. The primary amide was dehydrated to give the nitrile
26. Note that these simple chemical transformations allowed
us to generate various analogues with diﬀerent physicochem-
ical properties, in particular, hydrogen bond donor/acceptor
count, which allowed a good assessment of SAR.
The pyrazole moiety was modiﬁed by replacing one of the
methyl groups with a hydroxyl group. This was performed by
using aminoguanidine as the precursor and reacting it with a β-
keto ester33 such as ethyl acetoacetate to give a pyrazolone
derivative 28 (Scheme 4). The similar synthetic methodology
gave the 4-methylpyrazolone derivative 29. The β-keto ester
precursor 27 was synthesized using a TiCl4-mediated
condensation reaction. The pyrazolone derivatives then
underwent the ring formation reaction to create the desired
pyrimidine core (30 and 31).
The pyrazole moiety was replaced entirely with cyclic
saturated examples (Scheme 5). Three cyclic saturated
structures were used as examples: pyrrolidine, 2-methylpyrro-
lidine, and morpholine. To achieve this, unsubstituted 1H-
pyrazole-1-carboximidamide was used as a guanylating agent,
attaching the guanyl group to the nitrogen atom of the cyclic
saturated examples. These guanyl derivatives then underwent
the usual ring formation reaction to give the analogues 35−37.
This ring formation strategy was useful in exploring the
eﬀect of substitution on the 5-position of the pyrimidine core.
The starting compound 3,5-dimethyl-1H-pyrazole-1-carbox-
imidamide can be reacted with either β-keto ester 27 or
acrylates to give analogues 38, 39, and 42 (Scheme 6). As with
in Scheme 2, basic functional group transformation allowed the
generation of analogues with diverse physicochemical proper-
ties. It was interesting to note that the ethyl ester 39
underwent transesteriﬁcation to give 40 upon treatment of
methanolic ammonia; thus, a diﬀerent route was required to
obtain the amide 41. Direct synthesis of 42 gave a side
reaction, which was documented in the literature,34,35 thus an
alternative route was envisaged in which the amide 41 was
dehydrated to give 42.
Attempts were also made to change the pyrimidine core for
other heterocycles. At ﬁrst, pyridine was used with 2,6-
dichloropyridine derivatives as the starting point. The synthetic
scheme (Scheme 7) is similar to Scheme 1, but the
hydroxylation reaction required a copper-catalyzed reaction,
modiﬁed from Yang et al.36 and Wang et al.37 There were
limited number of pyridine examples, reasons of which will be
discussed in the later sections.
All in all, these synthetic methodologies provided convenient
methods to generate a diversity of analogues with varying
pharmacophoric and physicochemical properties (examples
shown in Figure S4). Furthermore, these synthetic methods
can be applied in parallel synthesis, thus allowing rapid
generation of analogues for SAR exploration.
Biological Evaluation of 2 and Its Analogues. The
analogues synthesized (excluding intermediates 27−29 and
32−34) were then tested using the 10-point dose−response
whole cell assay against S. aureus. Here, we noted the
challenges in evaluating biological activity for some of these
analogues. First, due to the low potency nature of small
fragment-like polar molecules, high concentrations were used
during the whole cell screening process. The dose−response
assay was performed with the modiﬁed top concentration of
1.8 mM, diluted threefold across 10 concentration points, to
better visualize the curve. As we have a maximum in-house
dimethyl sulfoxide (DMSO) concentration limit of 1% in
whole cell screening assays, the stock concentration for such
compounds was set to 200 mM. Unfortunately, analogues with
substituents on the 5-position of the pyrimidines (for example
16, 20, 39, 40, and 42) were found to be insoluble in DMSO
at 200 mM.
The resynthesized 2 retained its inhibitory activity against S.
aureus (Table 1). Some analogues have shown greater potency
of almost a log fold than the original hit compound, in
Scheme 4. Synthesis of 3 and Analogues from Pyrazolone
Derivativesa
aReagent and conditions: (a) TiCl4, triethylamine (TEA), DCM, 0
°C to rt, 4 h, 63%; (b) ethyl acetoacetate (for 28) or 27 (for 29),
NaOAc, H2O, overnight (or 7 days for 29), 52−64%; (c) ethyl
acetoacetate, NaOEt, EtOH, reﬂux, overnight, 28−38%.
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particular the benzyl ether analogues. Removal of the
substituent groups on the pyrimidine core of the original hit
2 reduces the potency. The SAR on the pyrazole core is
limited, with no other substituents having improved activity
from the original 3,5-dimethyl substituents. The replacement
of the pyrazole core with the saturated ring system removed
any compound activity. The focused set of analogues that has
been made cover a range of positions in the molecule and are
suﬃcient to validate the hit and indicate potential ways to
optimize the molecule. The overall SAR can be summarized in
Figure 4.
As well as the potency of the compounds against S. aureus,
various metrics were calculated. Ligand eﬃciency index
(LEI)38 is normally calculated for binding to a protein. LEI,
deﬁned as pEC50 divided by heavy atom count (HAC), is the
simpliﬁcation of LE in which the multiplier constant 1.37 was
not applied in the equation. The value of LEI describes the
extent of the improvement of the potency when more heavy
atoms are added to the active compound. Originally used in
the target-based fragment drug discovery, it can also be applied
to whole cell screens where it measures how well each atom
interacts with the molecular target and determines if
substituents contribute signiﬁcantly to the binding. Lipophilic
ligand eﬃciency (LLE)38 indicates whether the interactions are
driven by lipophilicity (Table 2).
Although compound 5 was the most potent compound,
much of the binding compared to compound 2 was probably
driven by lipophilicity of the benzyl group, as shown by the
drop in LLE. Compound 10, on the other hand, had improved
LEI and LLE compared to compound 2 and is the most
eﬃcient binder. It must be noted that compound 10 contains
Scheme 5. Synthesis Analogues of 2 by Replacing the Pyrazole with Saturated Ring Systema
aReagent and conditions: (a) various amines, TEA, MeCN, reﬂux, overnight, 74−85%; (b) ethyl acetoacetate, NaOEt, EtOH, reﬂux, overnight,
52−72%.
Scheme 6. Exploration of 5-Substituted Pyrimidine
Analoguesa
aReagent and conditions: (a) 27 (for 38) or appropriate acrylates (39
and 42), NaOH, EtOH, 100 °C, overnight, 19−50%; (b) NH3,
MeOH, reﬂux, overnight, 102%; (c) NH4OH, 75 °C, overnight, 86%;
(d) Burgess reagent, THF, rt, overnight, 20%.
Scheme 7. Pyridine Analogues of 2a
aReagent and conditions: (a) 3,5-dimethylpyrazole, KOH, 18-crown-
6, MeCN, MW 80 °C, 1.25−2.25 h, 50−55%; (b) tetrabutylammo-
nium hydroxide, CuI, 8-hydroxyquinoline 1-oxide, H2O, MW 180 °C,
3 h, 58−87%.
Table 1. Activity of 2 and Its Analogues against S. aureus
compound mean pEC50 (±SD)
a compound mean pEC50 (±SD) compound mean pEC50 (±SD)
2 3.9 (±0.05) 15 NA 31 NA
3 3.8 (±0.07) 16 NSc 35 NA
4 3.2 (±0.05) 17 NA 36 NA
5 4.8 (±0.16) 18 NA 37 NA
6 4.7 (±0.01) 19 3.2 (±0.20) 38 2.8 (±0.03)
7 3.0 (±0.23) 20 NS 39 NS
8 3.6 (±0.70) 21 NS 40 NS
9 4.6 (±0.07) 22 NS 41 NA
10 4.4 (±0.04) 23 NS 42 NS
11 NAb 24 NA 43 NA
12 NA 25 NA 44 NA
13 3.0 (±0.17) 26 NA 45 NA
14 NA 30 NA 46 NA
aExpressed as the mean and its respective standard deviation from three replicates. bNA = no activity at 1.8 mM. cNS = not soluble in DMSO stock
solution at 200 mM, hence not tested for compound activity.
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an α-chloropyrimidine, which is potentially chemically reactive.
In addition, compound 10 is less lipophilic than compound 5.
Metabolomics Study of 2 and Its Analogues and
Other Relevant Compounds. The original hit 2 and the two
selected compounds, 5 (highest potency) and 10 (highest
LEI), were then subjected to metabolomics to elucidate any
potential mode of action. Additionally, the other hit compound
from the whole cell screening assay, 1, was included in this
metabolomics study. Two approved antibiotics, ciproﬂoxacin
and trimethoprim, were also included in this study for
comparison.
The metabolomics study was based on the kill-kinetic
studies similar to those used by Vincent et al.,17 in which the
organism was exposed to an antibacterial agent and the eﬀect
monitored over time. The nature of the kill kinetics can be
aﬀected by the size of the starting inoculum and the dose of the
compound administered at the beginning of the study.
S. aureus RN6390, which has been studied for its virulence
and pathogenicity, was used, and it showed similar whole cell
response and sensitivity to the RN4220 strain (examples in
Table S1). Despite the subtle diﬀerences between the two
strains RN6390 and RN4220, both were classiﬁed as
methicillin sensitive and the lineage of these strains was traced
back to NCTC8325 (also known as RN1) strain. This gave a
hint of the whole cell similarity between the two strains and the
capability of these compounds to target metabolic pathways.
which are common and fundamental to these strains. The
strain RN6390 has also been described to be virulent in various
infection models39−41 and capable of producing α-toxins. On
the other hand, the strain RN4220, although is useful in
genetic manipulation studies, may contain mutations, which
may aﬀect virulence factors and strain ﬁtness,42 and hence the
change to the RN6390 strain for the metabolomics study.
The design of the metabolomics study was based on that of
Vincent et al.17 The minimal inhibitory concentration (MIC)
of each compound in this metabolomics study was determined
by the microdilution method (Table 3).
Using 4 times the MIC as the starting dose, the bacteria
were inoculated and incubated in fresh LB media for 2 h prior
to the administration of the compound, thus coinciding with
the exponential growth phase where bacterial metabolic
activity is most active. The metabolome was sampled at
intervals of 90 min to account for S. aureus doubling time. At
later time points, the bacteria are likely to be undergoing gross
changes in metabolites due to cell death. The earlier time
points are more likely to be representative of the speciﬁc
mechanism of action.
The metabolome extraction protocol was adapted from that
described by Vincent et al.,17 by including bead beating
alongside chemical extraction (with 1:3:1 chloroform−
methanol−water as the solvent) to obtain the internal
metabolome.43 Glass beads were used as previously
described43−46 for the extraction of metabolites from S. aureus.
Metabolome samples were analyzed by Glasgow Polyomics,
University of Glasgow. The levels of metabolites and the
identiﬁcation of metabolites were determined based on the
methods by Vincent et al.17 The comparison of metabolite
Figure 4. Summary of the SAR of 2.
Table 2. Ligand Eﬃciency Analysis of Active Compounds
compound MW HACa clog P mean pEC50 LEI
b LLEc
1d 249 17 3.0 3.6 0.21 0.6
2 204 15 1.0 3.9 0.26 2.9
3 223 15 1.6 3.8 0.24 2.2
4 243 15 2.1 3.2 0.21 1.1
5 324 24 3.1 4.8 0.20 1.7
6 324 24 3.1 4.7 0.20 1.6
7 324 24 3.4 3.0 0.13 −0.4
8 312 23 3.2 3.6 0.16 0.4
9 294 22 2.8 4.6 0.21 1.8
10 225 15 1.2 4.4 0.30 3.2
13 202 15 1.5 3.0 0.20 1.5
19 190 14 0.6 3.2 0.24 2.6
38 218 16 0.5 2.8 0.18 2.3
aHeavy atom count. bLigand eﬃciency index, deﬁned as pEC50/HAC.
cLipophilic ligand eﬃciency, deﬁned as pEC50 − clog P. dCompound
1 was repurchased and retested for activity.
Table 3. Comparison of MIC Values among Various
Compounds Showing Inhibitory Activity against S. aureus
RN6390
compound MIC (μg/mL)a
1 64
2 32
5 4
10 16
ciproﬂoxacin 0.25
trimethoprim 2
aDetermined through the microdilution method in Luria−Bertani
(LB) media.
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levels was initially performed using principal component
analysis (PCA). A PCA plot is useful to reduce multidimen-
sional data such as the data gathered in this study, as each data
point consists of the various intensities of metabolites detected
in each sample. By reducing multidimensional data to two- or
three-dimensional data, a PCA plot presents a clear visual
representation to identify any clustering of data, which gives an
indication of similarity with one another. Figure 5 shows the
eﬀect of various compounds exhibiting antibacterial activity on
the bacterial metabolome, visualized using PCA plots.
Ciproﬂoxacin has previously been shown to cause drastic
changes to the nucleotide pool,46 and we also noted similar
changes, in particular, in cytidine and guanine pool (Table S2).
Trimethoprim inhibits dihydrofolate reductase (DHFR), but
the folate pool was of insuﬃcient abundance to be identiﬁed in
the liquid chromatography−mass spectrometry platform we
used. A signiﬁcant increase in uridine is likely related to an
accumulation of deoxyuridine monophosphate as its methyl-
ation to deoxythymidine monophosphate (not identiﬁed) is
prevented as DHFR is inhibited depriving the cells of the key
methyl group donor used in DNA synthesis.
The observation that 2 and its two analogues have distinct
clusters from the rest suggests that these compounds have the
same/similar mode of action. However, although changes of
metabolites were observed upon treatment with 2 and its two
analogues, no metabolic pathways stood out as speciﬁc targets
for these compounds based on clear changes in abundance
across a single enzyme. This could indicate that 2 and its
analogues act against a target, which has pleiotropic eﬀects,
against several targets, or the compound could act against
targets with metabolites poorly represented in the database.
As ciproﬂoxacin and trimethoprim target nucleic acid
metabolism (DNA and folate biosynthesis, respectively), it
was interesting to observe that this general similarity in their
mode of action translated to similar clustering in the PCA plot
in Figure 5. Based on these clustering patterns, it can be
suggested that the modes of action of 2 and its analogues are
distinct compared to ciproﬂoxacin and trimethoprim. In
addition, the clustering also suggests that compound 1 may
have a distinct mode of action from the rest of the compounds
tested. Nevertheless, the results from these early metabolomics
studies must be supported by other orthogonal biological
studies to generate or further strengthen a hypothesis on the
mode of action.
These early results presented the challenge of determining
the right moment in an early antibacterial drug discovery
program for these compounds to be subjected to metab-
olomics study. As these compounds (excluding marketed
antibiotics) are small polar molecules with low potency, there
is always the possibility of their exerting activity at multiple
targets across bacterial metabolism. In this case, during hit
expansion to improve the potency of the analogues, the mode
of action can shift. As seen in Figure 5, the more potent
compound 5 seems to have a diﬀerent metabolic ﬁngerprint
from its original hit 2. This may indicate that metabolomics
can be useful to monitor whether SAR exploration may lead to
a switch in the mechanism of action.
■ CONCLUSIONS
We have introduced the notion of small polar molecules as an
attractive starting point in antibacterial drug discovery. This
requires a well-constructed library to provide new chemical
scaﬀolds with good physicochemical properties and novelty to
allow eﬃcient chemical expansion and optimization.
The whole cell screening process was designed to be
amenable to high-throughput conditions, with straightforward
set-up and easy-to-measure end points. From our in-house
whole cell screening assay using our small polar library, we
have identiﬁed two promising hit compounds, 1 and 2. The hit
expansion of 2 has been illustrated in detail in this article, with
diverse chemistry to probe the eﬀect of various substitutions
on the pyrazoloylpyrimidine core. This diverse chemistry can
be amenable to parallel combinatorial chemistry to allow quick
synthesis of analogues as well. Some initial SAR can be
observed from these analogues synthesized, with compounds
such as 5 and 10 gaining potency from the original hit.
Although the original low-molecular-weight hit had relatively
weak activity (but good ligand eﬃciency), it was possible to
optimize it to a compound with much greater potency, not
much less potent than trimethoprim, a clinically used
antibiotic. As such, we believe that this series has the potential
for further rounds of chemical optimization to improve
potency and physicochemical properties, using ligand
eﬃciency metrics as indicators. As physicochemical properties
of these compounds are important in ensuring not only
optimal entry into the bacteria but also pharmacokinetic
properties, we would suggest using ligand eﬃciency metrics
such as LEI and LLE to guide the direction of the chemical
optimization.
Early metabolomics study indicated that 2 and its analogues,
alongside the other whole cell hit 1, have distinct mode of
actions compared to other antibiotics tested (ciproﬂoxacin and
trimethoprim), even though the mode of actions for 2 and its
analogues (alongside 1) cannot be precisely determined. It is
also interesting to note the shift in the mode of action as the
compound is optimized. This is perhaps not surprising. A
Figure 5. PCA plot of drug treatments on S. aureus RN6390. Raw
intensities were glog transformed and the plot was generated using the
MetaboAnalyst software.47 Time points are combined for clarity and
one outlier from the treatment group 5 was removed as it had much
lower intensities across the entire spectrum.
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weak, although ligand eﬃcient, low-molecular-weight com-
pound may inhibit several targets weakly. However, during
compound optimization, the proﬁle of which molecular targets
is inhibited and by how much, may change.
Determining the precise mode of action of a molecular
target can be very challenging. A future study to derive the
metabolomic ﬁngerprint of key antibiotics will be important as
a reference to compare to new compounds would be very
valuable. Orthogonal mode of action studies such as chemical
proteomics or resistance generation followed by whole genome
sequencing can also be proposed to support any hypothesis
from this untargeted metabolomics approach.
Despite the limitations discussed, we are optimistic that
whole cell screening coupled with metabolomic can be an
attractive route to ﬁnding new starting points with novel
modes of action in early antibacterial drug discovery. The work
of Pogliano has shown that there is a distinct phenotype
associated with compounds, which target particular pathways
within bacteria.48 There is a scope for extending this current
work, by seeing if there is a correlation between the
metabolome ﬁngerprint and the morphological eﬀect on the
bacteria. This whole cell-based platform highlights the
capability for ﬁnding new hits with cellular activity and
potential new mode of action. The mode of action can then be
validated at the early stages of hit discovery, which then
increases the odds of success for the drug development
process.
■ EXPERIMENTAL SECTION
Whole Cell Screening. The whole cell screening was
performed using the in-house small polar library. The
composition of the library and some illustrated examples of
synthesis of such molecules were described by Ray et al.22
Compounds from the library were stamped into each well from
column 1 to column 22 of 384-well plates with a Echo 550
Liquid Handler (Labcyte Inc.). S. aureus RN4220 (Division of
Molecular Microbiology, University of Dundee) was used for
whole cell screening. All cultures, which require shaking, were
shaken at 200 rpm. An overnight culture was prepared by
culturing a colony in 3 mL (for S. aureus RN4220) of fresh LB
media (Central Technical Services, University of Dundee) at
37 °C for 12−15 h. The culture was dispensed into white-
walled, clear ﬂat-bottom 384-well plates (Greiner Bio-One) by
a Multidrop Combi Reagent Dispenser (Thermo Scientiﬁc).
Plates were read using PHERAstar FS (BMG LABTECH). 50
μL of the culture (prepared by diluting an overnight culture of
S. aureus RN4220 with fresh LB media at 1:400 ratio) was
added to columns of each well, depending on the type of
study: single-point study (columns 1−22 of the plate) or
(columns 1−10 and 13−22 of the plate). The positive control
(gentamicin 0.5 mg/mL) was ﬁlled into column 23 (for single-
point study) or columns 11 and 23 (for dose−response study),
while the negative control (no drug) was ﬁlled in the
remaining columns. The plates were sealed with air-permeable
seals (AeraSeal, Excel Scientiﬁc, Inc.) and incubated still at 37
°C for 6 h. The plate was then put into a plate reader to
measure OD600nm. All calculations were performed on
ActivityBase XE (IDBS) using the raw data obtained from
the plate reader. The raw data correspond to the OD600nm
measured on each well. PA positive control is deﬁned as a
completely active compound with 100% inhibitory eﬀect
against bacteria. The negative control is deﬁned as a
completely inactive compound with 0% inhibitory eﬀect
against bacteria. Hit analysis was performed and visualized
using Vortex (Dotmatics Limited). Graphic visualization and
statistical analysis were performed and visualized using Vortex
and GraphPad Prism 6 (GraphPad Software Inc.).
Chemistry. General Procedures. Chemicals and solvents
were purchased from Aldrich Chemical Co., Acros, TCI, and
Fluorochem. Analytical thin-layer chromatography (TLC) was
performed on precoated TLC plates (layer 0.20 mm silica gel
60 with ﬂuorescent indicator UV 254, from Merck).
Developed plates were air-dried and analyzed under a UV
lamp (UV 254/365 nm) or sprayed with a potassium
permanganate solution to visualize oxidizable substances.
Flash column chromatography was performed using prepacked
silica gel cartridges (Teledyne ISCO) using CombiFlash
Rf200i (Teledyne ISCO). Microwave-assisted chemistry was
conducted using a Biotage initiator microwave synthesizer. 1H
and 13C NMR spectra were recorded on a Bruker ARX-500
spectrometer (500, 470, and 125 MHz for 1H, 19F, and 13C
NMR, respectively). Spectra were acquired using DMSO-d6,
D2O, and CDCl3 as solvents. Chemical shifts (δ) are reported
in parts per million relative to the residual solvent peak as the
internal reference, and coupling constants (J) are reported in
hertz (Hz). Coupling constants are assumed to be H−H
coupling constants unless stated otherwise. The spin multi-
plicity is reported as s = singlet, s(b) = broad singlet, d =
doublet, t = triplet, q = quartet, m = multiplet. LC−MS
analyses were performed with either an Agilent HPLC 1100
series connected to a Bruker Daltonics MicrOTOF or an
Agilent Technologies 1200 series HPLC connected to an
Agilent Technologies 6130 quadrupole spectrometer, where
both instruments were connected to an Agilent diode array
detector. LC−MS chromatographic separations were con-
ducted with a Waters X bridge C18 column, 50 mm × 2.1 mm,
3.5 μm particle size; mobile phase, H2O/MeCN + 0.1%
HCOOH, or H2O/MeCN + 0.1% NH3; linear gradient from
80:20 to 5:95 over 3.5 min and then held for 1.5 min; ﬂow rate
of 0.5 mL/min. High-resolution electrospray measurements
were performed on a Bruker Daltonics MicrOTOF mass
spectrometer. All assay compounds had a measured purity of
≥95% (by TLC and UV) as determined using both LC−MS
and NMR spectroscopy. Melting points were determined on
the Griﬃn melting point apparatus and were uncorrected.
General Procedure A for the Coupling of Chloropyr-
imidines and 3,5-Dimethylpyrazoles. Method 1 (Com-
pounds 3, 4, and 17). To a solution of appropriate
chloropyrimidine (1 equiv) in dioxane (0.2 M) was added
3,5-dimethylpyrazole (1.05 equiv) and was subjected to
microwave irradiation at 150 °C for 3 h. The solvent was
removed, and the crude residue was puriﬁed using ﬂash
column chromatography (DCM/heptane or EtOAc/heptane)
to give the intended product.
Method 2 (Compounds 12−16). To a solution of
appropriate chloropyrimidine (1 equiv) in acetonitrile (0.33
M) were added 3,5-dimethylpyrazole (1 equiv), KOH (1
equiv), and 18-crown-6 (0.1 equiv). The reaction mixture was
left to stir at rt for 1 day or was subjected to microwave
irradiation at various temperatures. The reaction mixture was
quenched with 2 M HCl, and the aqueous layer was extracted
with ethyl acetate. The organic layer was then separated and
concentrated in vacuo to give the residue, which was then
puriﬁed using ﬂash column chromatography (0−25% EtOAc in
heptane) to give the intended product.
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4-Chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyri-
midine (3). General procedure A, method 1, from 2,4-
dichloro-6-methylpyrimidine (163 mg, 1.0 mmol). Chromato-
graphic puriﬁcation (50% DCM in heptane to 100% DCM)
gave compound 3 as white solid (79 mg, 35%): mp: 58−60 °C
(lit. mp 57 °C49); 1H NMR (CDCl3, 500 MHz) δ: 7.06 (s, 1H,
Ar H), 6.07 (s, 1H, Ar H), 2.68 (s, 3H, CH3), 2.61 (s, 3H,
CH3) 2.36 (s, 3H, CH3).
13C NMR (CDCl3, 125 MHz) δ:
170.9 (C), 161.6 (C), 156.8 (C), 152.1 (C), 143.5 (C), 117.0
(CH), 110.9 (CH), 24.2 (CH3), 15.5 (CH3), 14.0 (CH3); MS
[electrospray ionization (ESI)] m/z 223 [M + H]+ (35Cl); 225
[M + H]+ (37Cl); high-resolution mass spectrometry (HRMS)
(ESI) m/z: calcd for C10H12N4Cl
+ [M + H]+, 223.0745; found,
223.0755.
4,6-Dichloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidine
(4). General procedure A, method 1, from 2,4,6-trichloropyr-
imidine (575 μL, 917 mg, 5.0 mmol). Chromatographic
puriﬁcation (50% DCM in heptane to 100% DCM) gave
compound 4 as white solid (295 mg, 24%): mp 110−111 °C;
1H NMR (CDCl3, 500 MHz) δ: 7.21 (s, 1H, Ar H), 6.08 (s,
1H, Ar H), 2.68 (s, 3H, CH3), 2.35 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 162.7 (2× C), 156.4 (C), 153.2 (C),
144.1 (C), 117.1 (CH), 111.8 (CH), 15.6 (CH3), 14.0 (CH3);
MS (ESI) m/z 243 [M + H]+; 245 [M + H]+ (35Cl37Cl); 247
[M + H]+ (37Cl37Cl); HRMS (ESI) m/z: calcd for C9H9N4Cl2
+
[M + H]+, 243.0199; found, 243.0213.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)pyrimidine (12). General
procedure A, method 2, from 2-chloropyrimidine (115 mg, 1.0
mmol) and stirred at rt. Chromatographic puriﬁcation gave
compound 12 as brown oil (77 mg, 44%): 1H NMR (CDCl3,
500 MHz) δ: 8.76 (d, J = 4.8 Hz, 2H, 2× Ar H), 7.19 (t, J = 4.8
Hz, 1H), 6.07 (s, 1H, Ar H), 2.69 (s, 3H, CH3), 2.36 (s, 3H,
CH3);
13C NMR (CDCl3, 125 MHz) δ: 158.4 (2× CH), 157.6
(C), 151.5 (C), 143.0 (C), 117.7 (CH), 110.3 (CH), 15.3
(CH3), 13.8 (CH3); MS (ESI) m/z 175 [M + H]
+; HRMS
(ESI) m/z: calcd for C9H11N4
+ [M + H]+, 175.0978; found,
175.0979.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4,6-dimethylpyrimidine
(13). General procedure A, method 2, from 2-chloro-4,6-
dimethylpyrimidine (143 mg, 1.0 mmol) and subjected to
microwave irradiation at 80 °C for 15 min. Chromatographic
puriﬁcation gave compound 13 as brown oil (96 mg, 47%): 1H
NMR (CDCl3, 500 MHz) δ: 6.90 (s, 1H, Ar H), 6.03 (s, 1H,
Ar H), 2.66 (s, 3H, CH3), 2.55 (s, 6H, 2× CH3), 2.36 (s, 3H,
CH3);
13C NMR (CDCl3, 125 MHz) δ: 168.5 (C), 157.2 (C),
151.0 (C), 142.7 (C), 116.9 (CH), 109.9 (CH), 24.1 (2×
CH3), 15.2 (CH3), 14.0 (CH3); MS (ESI) m/z 203 [M + H]
+;
HRMS (ESI) m/z: calcd for C11H14N4
+ [M + H]+, 203.1291;
found, 203.1303.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-methoxypyrimidine
(14). General procedure A, method 2, from 2-chloro-4-
methoxypyrimidine (434 mg, 3.0 mmol) and subjected to
microwave irradiation at 120 °C for 30 min. Chromatographic
puriﬁcation gave compound 14 as white solid (196 mg, 32%):
mp 91−92 °C; 1H NMR (CDCl3, 500 MHz) δ: 8.49 (d, J =
5.7 Hz, 1H, Ar H), 6.59 (d, J = 5.7 Hz, 1H, Ar H), 6.06 (s, 1H,
Ar H), 4.05 (s, 3H, CH3), 2.72 (s, 3H, CH3), 2.36 (s, 3H,
CH3);
13C NMR (CDCl3, 125 MHz) δ: 170.3 (C), 158.7
(CH), 157.0 (C), 151.4 (C), 142.6 (C), 110.4 (CH), 104.7
(CH), 54.3 (OCH3), 15.6 (CH3), 13.9 (CH3); MS (ESI) m/z
205 [M + H]+; HRMS (ESI) m/z: calcd for C10H13N4O
+ [M +
H]+, 205.1084; found, 205.1097.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4,6-dimethoxypyrimi-
dine (15). General procedure A, method 2, from 2-chloro-4,6-
dimethoxypyrimidine (524 mg, 3.0 mmol) and stirred at rt.
Chromatographic puriﬁcation gave compound 15 as white
solid (492 mg, 70%): mp 102−104 °C; 1H NMR (CDCl3, 500
MHz) δ: 6.03 (s, 1H, Ar H), 5.93 (s, 1H, Ar H), 4.03 (s, 6H,
2× CH3), 2.69 (s, 3H, CH3), 2.34 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 172.1 (2× C), 156.1 (C), 151.3 (C),
142.8 (C), 110.3 (CH), 86.7 (CH), 54.5 (2× OCH3), 15.6
(CH3), 14.0 (CH3); MS (ESI) m/z 235 [M + H]
+; HRMS
(ESI) m/z: calcd for C11H15N4O2
+ [M + H]+, 235.1190;
found, 235.1208.
5-Chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-methoxypyr-
imidine (16). General procedure A, method 2, from 2,5-
dichloro-4-methoxypyrimidine (263 mg, 1.47 mmol) and
stirred at rt. Chromatographic puriﬁcation gave compound
16 as white solid (144 mg, 41%): mp 132−133 °C; 1H NMR
(CDCl3, 500 MHz) δ: 8.50 (s, 1H, Ar H), 6.07 (s, 1H, Ar H),
4.15 (s, 3H, OCH3), 2.70 (s, 3H, CH3), 2.35 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ: 165.2 (C), 156.8 (CH),
154.7 (C), 151.9 (C), 142.7 (C), 113.2 (C), 110.7 (CH), 55.4
(CH3), 15.5 (CH3), 13.9 (CH3); MS (ESI) m/z 239 [M + H]
+
(35Cl); 227 [M + H]+ (37Cl); HRMS (ESI) m/z: calcd for
C10H12N4OCl
+ [M + H]+, 239.0694; found, 239.0725.
Methyl 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-methylpyrimi-
dine-4-carboxylate (17). General procedure A, method 1,
from methyl 2-chloro-6-methylpyrimidine-4-carboxylate (1.88
g, 10.1 mmol). Chromatographic puriﬁcation (0−25% EtOAc
in heptane) gave compound 17 as yellow solid (1.60 g, 64%):
1H NMR (CDCl3, 500 MHz) δ: 7.70 (s, 1H, Ar H), 6.08 (s,
1H, Ar H), 4.03 (s, 3H, OCH3), 2.73 (s, 3H, CH3), 2.73 (s,
3H, CH3), 2.37 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz)
δ: 171.5 (C), 164.0 (C), 156.9 (C), 155.1 (C), 151.3 (C),
142.8 (C), 116.2 (CH), 110.0 (CH), 52.6 (CH3), 24.1 (CH3),
14.7 (CH3), 13.4 (CH3); MS (ESI) m/z 247 [M + H]
+;
HRMS (ESI) m/z: calcd for C12H15N4O2
+ [M + H]+,
247.1190; found, 247.1215.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidin-4-ol
(2). To a solution of 4,6-dichloro-2-(3,5-dimethyl-1H-pyrazol-
1-yl)pyrimidine (3) (179 mg, 0.80 mmol) in THF (4 mL) was
added 1 M NaOH (4 mL) and then subjected to microwave
irradiation at 150 °C for 30 min. Excess base was neutralized
with 2 M HCl, and the reaction mixture was extracted with
ethyl acetate. The organic phase was separated and
concentrated in vacuo. The residue was then puriﬁed using
ﬂash column chromatography (0−3% MeOH in DCM) to give
3 as a white solid (148 mg, 90%): mp 126−126 °C (lit. mp
135−137 °C49); 1H NMR (CDCl3, 500 MHz) δ: 10.40 (s(b),
1H, OH), 6.08 (s, 1H, Ar H), 6.05 (s, 1H, Ar H), 2.69 (s, 3H,
CH3), 2.30 (s, 3H, CH3), 2.27 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 165.1 (C), 161.9 (C), 151.9 (C), 147.5
(C), 143.6 (C), 111.5 (CH), 108.9 (CH), 24.0 (CH3), 15.1
(CH3), 13.6 (CH3); MS (ESI) m/z 205 [M + H]
+; HRMS
(ESI) m/z: calcd for C10H13N4O
+ [M + H]+, 205.1084; found,
205.1091.
Alternative Procedure Using TFA−DCM. To 2-(3,5-
dimethyl-1H-pyrazol-1-yl)-4-((4-methoxybenzyl)oxy)-6-meth-
ylpyrimidine (5) (49 mg, 0.15 mmol) was added excess
volume of triﬂuoroacetic acid (200 equiv) and an equivalent
volume of DCM. The reaction mixture was left to stir for 1 h at
rt. The reaction mixture was evaporated in vacuo, and the
residue was puriﬁed by reverse-phase UV-HPLC to give 2 as a
white solid (22 mg, 72%).
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6-Chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-ol
(10). To a solution of 4,6-dichloro-2-(3,5-dimethyl-1H-
pyrazol-1-yl)pyrimidine (4) (100 mg, 0.41 mmol) in THF
(2.05 mL) were added 1 M NaOH (0.82 mL) and additional
water (1.23 mL) and then subjected to microwave irradiation
at 150 °C for 30 min. Excess base was neutralized with 2 M
HCl, and the reaction mixture was extracted with ethyl acetate.
The organic phase was separated and concentrated in vacuo.
The residue was then puriﬁed using ﬂash column chromatog-
raphy (DCM) to give 10 as a white solid (63 mg, 68%): mp
132−134 °C; 1H NMR (CDCl3, 500 MHz) δ: 10.50 (s(b),
1H, OH), 6.29 (s, 1H, Ar H), 6.04 (s, 1H, Ar H), 2.69 (s, 3H,
CH3), 2.28 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ:
160.4 (C), 158.8 (C), 153.2 (C), 147.4 (C), 144.3 (C), 112.3
(CH), 109.3 (CH), 15.0 (CH3), 13.6 (CH3); MS (ESI) m/z
225 [M + H]+ (35Cl); 227 [M + H]+ (37Cl); HRMS (ESI) m/
z: calcd for C9H10N4ClO
+ [M + H]+, 225.0538; found,
225.0497.
General Procedure B for the Formation of Benzyl Ether
Analogues (Compounds 5−9). To a solution of 4-chloro-2-
(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidine (3) (1
equiv) in acetonitrile (0.3 M) were added the appropriate
benzyl alcohol (1.2 equiv) and Cs2CO3 (1.2 equiv). The
reaction mixture was then reﬂuxed overnight. The reaction
mixture was then cooled to rt and diluted with ethyl acetate.
The organic phase was then washed with brine, dried, and
concentrated in vacuo. The crude product was then puriﬁed
using ﬂash column chromatography (0−50% ethyl acetate in
heptane) to give the desired product.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-((4-methoxybenzyl)-
oxy)-6-methylpyrimidine (5). General procedure B, from 4-
methoxybenzyl alcohol (350 mg, 2.53 mmol) to give 5 as white
solid (542 mg, 79%): mp 58−60 °C; 1H NMR (CDCl3, 500
MHz) δ: 7.37 (d, J = 8.7 Hz, 2H, 2× Ar H), 6.93 (d, J = 8.7
Hz, 2H, 2× Ar H), 6.48 (s, 1H, Ar H), 6.04 (s, 1H, Ar H), 5.39
(s, 2H, CH2), 3.84 (s, 3H, OCH3), 2.69 (s, 3H, CH3), 2.54 (s,
3H, CH3), 2.36 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz)
δ: 170.1 (C), 169.6 (C), 159.7 (C), 156.6 (C), 151.2 (C),
142.5 (C), 129.8 (2× CH), 128.0 (C), 114.1 (2× CH), 110.2
(CH), 103.6 (CH), 68.4 (CH2), 55.3 (CH3), 24.3 (CH3), 15.5
(CH3), 14.0 (CH3); MS (ESI) m/z 325 [M + H]
+; HRMS
(ESI) m/z: calcd for C18H21N4O2
+ [M + H]+, 325.1659;
found, 325.1685.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-((3-methoxybenzyl)-
oxy)-6-methylpyrimidine (6). General procedure B, from 3-
methoxybenzyl alcohol alcohol (67 μL, 74 mg, 0.54 mmol) to
give 6 as white solid (52 mg, 36%): 1H NMR (CDCl3, 500
MHz) δ: 7.23 (dd, J1 = 7.9 Hz, J2 = 7.9 Hz, 1H, Ar H), 6.93−
6.90 (m, 1H, Ar H), 6.90−6.88 (m, 1H, Ar H), 6.82−6.79 (m,
1H, Ar H), 6.43 (s, 1H, Ar H), 5.94 (s, 1H, Ar H), 5.34 (s, 2H,
CH2), 3.74 (s, 3H, OCH3), 2.56 (s, 3H, CH3), 2.47 (s, 3H,
CH3), 2.27 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ:
170.1 (C), 169.8 (C), 159.8 (C), 156.6 (C), 151.2 (C), 142.6
(C), 137.5 (C), 129.7 (CH), 120.0 (CH), 113.7 (CH), 113.4
(CH), 110.2 (CH), 103.6 (CH), 68.4 (CH2), 55.3 (CH3),
24.3 (CH3), 15.5 (CH3), 14.0 (CH3); MS (ESI) m/z 325 [M
+ H]+; HRMS (ESI) m/z: calcd for C18H21N4O2
+ [M + H]+,
325.1659; found, 325.1610.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-((2-methoxybenzyl)-
oxy)-6-methylpyrimidine (7). General procedure B, from 2-
methoxybenzyl alcohol (72 μL, 74 mg, 0.54 mmol) to give 7 as
white solid (55 mg, 38%): 1H NMR (CDCl3, 500 MHz) δ:
7.39−7.38 (m, 1H, Ar H), 7.34 (td, J1 = 7.9 Hz, J2 = 1.6 Hz,
1H, Ar H), 6.98 (td, J1 = 7.5 Hz, J2 = 1.0 Hz, 1H, Ar H), 6.93−
6.95 (m, 1H, Ar H), 6.52 (s, 1H, Ar H), 6.02 (s, 1H, Ar H),
5.50 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 2.63 (s, 3H, CH3),
2.56 (s, 3H, CH3), 2.36 (s, 3H, CH3);
13C NMR (CDCl3, 125
MHz) δ: 170.2 (C), 169.6 (C), 157.4 (C), 156.6 (C), 151.1
(C), 142.7 (C), 129.5 (CH), 129.2 (CH), 124.3 (C), 120.5
(CH), 110.4 (CH), 110.1 (CH), 103.5 (CH), 64.1 (CH2),
55.4 (CH3), 24.3 (CH3), 15.3 (CH3), 14.0 (CH3); MS (ESI)
m/z 325 [M + H]+; HRMS (ESI) m/z: calcd for C18H21N4O2
+
[M + H]+, 325.1659; found, 325.1599.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-((4-ﬂuorobenzyl)oxy)-
6-methylpyrimidine (8). General procedure B, from 4-
ﬂuorobenzyl alcohol (70 μL, 82 mg, 0.65 mmol) to give 8 as
white solid (132 mg, 78%): 1H NMR (CDCl3, 500 MHz) δ:
7.33 (dd, 3JHH = 8.8 Hz,
4JHF = 5.4 Hz, 2H, 2× Ar H), 7.00
(dd, 3JHH = 8.7 Hz,
3JHF = 8.7 Hz, 2H, 2× Ar H), 6.41 (s, 1H,
Ar H), 5.95 (s, 1H, Ar H), 5.33 (s, 2H, CH2), 2.57 (s, 3H,
CH3), 2.46 (s, 3H, CH3), 2.27 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 170.0 (C), 169.8 (C), 162.7 (d,
1JCF =
247.2 Hz, C), 156.5 (C), 151.3 (C), 142.5 (C), 131.8 (C),
129.9 (d, 3JCF = 8.2 Hz, 2× CH), 115.6 (d,
2JCF = 21.7 Hz, 2×
CH), 110.3 (CH), 103.5 (CH), 67.8 (CH2), 24.3 (CH3), 15.5
(CH3), 14.0 (CH3);
19F NMR (CDCl3, 470 MHz) δ: −113.6
(Ar F); MS (ESI) m/z 313 [M + H]+; HRMS (ESI) m/z:
calcd for C17H18FN4O
+ [M + H]+, 313.1459; found, 313.1393.
4-(Benzyloxy)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-
pyrimidine (9). General procedure B, from benzyl alcohol (56
μL, 58 mg, 0.54 mmol) to give 9 as white solid (71 mg, 54%):
1H NMR (CDCl3, 500 MHz) δ: 7.45−7.35 (m, 5H, 5× Ar H),
6.52 (s, 1H, Ar H), 6.04 (s, 1H, Ar H), 5.47 (s, 2H, CH2), 2.66
(s, 3H, CH3), 2.56 (s, 3H, CH3), 2.36 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 170.1 (C), 169.8 (C), 156.6 (C), 151.3
(C), 142.6 (C), 136.0 (C), 128.6 (2× CH), 128.3 (CH), 127.9
(2× CH), 110.2 (CH), 103.6 (CH), 68.5 (CH2), 24.3 (CH3),
15.5 (CH3), 14.0 (CH3); MS (ESI) m/z 295 [M + H]
+;
HRMS (ESI) m/z: calcd for C17H19N4O
+ [M + H]+, 295.1553;
found, 295.1553.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-3,6-dimethylpyrimidin-
4(3H)-one (11). To a solution of 2-(3,5-dimethyl-1H-pyrazol-
1-yl)-6-methylpyrimidin-4-ol (2) (51 mg, 0.25 mmol) and
K2CO3 (69 mg, 0.50 mmol) in DMF (2.77 mL) was added
methyl iodide (62 μL, 1.00 mmol). The reaction was then
reﬂuxed overnight. Water was added into the reaction mixture,
and the reaction mixture was washed with ethyl acetate. The
organic phase was then separated, dried, and concentrated in
vacuo to give a residue, which was puriﬁed using ﬂash column
chromatography (10−25% ethyl acetate in heptane) to give 11
as a oﬀ-brown solid (41 mg, 75%): 1H NMR (CDCl3, 500
MHz) δ: 6.24 (s, 1H, Ar H), 5.94 (s, 1H, Ar H), 3.34 (s, 3H,
NCH3), 2.28 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.20 (s, 3H,
CH3);
13C NMR (CDCl3, 125 MHz) δ: 163.1 (C), 162.1 (C),
151.5 (C), 148.3 (C), 142.4 (C), 111.4 (CH), 108.1 (CH),
32.2 (CH3), 23.4 (CH3), 13.6 (CH3), 11.8 (CH3); MS (ESI)
m/z 219 [M + H]+; HRMS (ESI) m/z: calcd for C11H15N4O
+
[M + H]+, 219.1240; found, 219.1243.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidine-4-
carboxylic Acid (18). To a solution of methyl 2-(3,5-dimethyl-
1H-pyrazol-1-yl)-6-methylpyrimidine-4-carboxylate (17) (231
mg, 0.94 mmol) in 1:1 THF/H2O (14 mL) was added lithium
hydroxide (79 mg, 1.88 mmol), and the reaction mixture was
allowed to stir overnight at rt. The reaction mixture was
concentrated in vacuo, and the residue was puriﬁed using
mass-directed HPLC to give 18 as a white solid (190 mg,
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87%): 1H NMR (CDCl3, 500 MHz) δ: 7.82 (s, 1H, Ar H),
7.07 (s(b), 1H, OH), 6.10 (s, 1H, Ar H), 2.74 (s, 3H, CH3),
2.70 (s, 3H, CH3), 2.35 (s, 3H, CH3);
13C NMR (CDCl3, 125
MHz) δ: 172.3 (C), 164.3 (C), 156.5 (C), 155.5 (C), 152.0
(C), 143.7 (C), 116.2 (CH), 111.0 (CH), 24.6 (CH3), 15.6
(CH3), 13.6 (CH3); MS (ESI) m/z 233 [M + H]
+; HRMS
(ESI) m/z: calcd for C11H14N4O2
+ [M + H]+, 233.1033;
found, 233.1056.
General Procedure C for the O-Demethylation of
Methoxypyrimidines Using LiCl (Compounds 19−22). To a
solution of the suitable methoxypyrimidines (1 equiv) in DMF
(0.2 M) was added LiCl (3 equiv unless otherwise stated). The
reaction mixture was subjected to microwave irradiation at 160
°C for 30 min (unless otherwise stated). The reaction was then
acidiﬁed with dilute HCl. The aqueous layer was then
extracted with DCM. The organic phase was then collected
and concentrated in vacuo to give the residue, which was
puriﬁed using UV-directed HPLC to yield the appropriate
product.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)pyrimidin-4-ol (19). Gen-
eral procedure C, from 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-
methoxypyrimidine (14) (41 mg, 0.20 mmol) to give 19 as oﬀ-
brown solid (37 mg, 97%): mp 99−100 °C; 1H NMR (CDCl3,
500 MHz) δ: 10.56, (s(b), 1H, OH), 7.84 (d, J = 6.7 Hz, 1H,
Ar H), 6.24 (d, J = 6.6 Hz, 1H, Ar H), 6.07 (s, 1H, Ar H), 2.68
(s, 3H, CH3), 2.28 (s, 3H, CH3);
13C NMR (CDCl3, 125
MHz) δ: 161.2 (C), 154.1 (CH), 152.2 (C), 143.7 (C), 111.9
(CH), 111.7 (CH), 15.0 (CH3), 13.6 (CH3); MS (ESI) m/z
191 [M + H]+; HRMS (ESI) m/z: calcd for C9H11N4O
+ [M +
H]+, 191.0927; found, 191.0928.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-methoxypyrimidin-4-
ol (20). General procedure C, from 2-(3,5-dimethyl-1H-
pyrazol-1-yl)-4,6-dimethoxypyrimidine (15) (47 mg, 0.20
mmol) to give 20 as white solid (38 mg, 86%): mp 189−
191 °C; 1H NMR (CDCl3, 500 MHz) δ: 10.20 (s(b), 1H,
OH), 5.99 (s, 1H, Ar H), 5.42 (s, 1H, Ar H), 3.83 (s, 3H,
OCH3), 2.61 (s, 3H, CH3), 2.18 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 170.6 (C), 163.1 (C), 152.7 (C), 147.9
(C), 143.5 (C), 111.9 (CH), 87.4 (CH), 55.1 (CH3), 15.1
(CH3), 13.6 (CH3); MS (ESI) m/z 222 [M + H]
+; HRMS
(ESI) m/z: calcd for C10H13N4O2
+ [M + H]+, 221.1033;
found, 221.1043.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)pyrimidine-4,6-diol (21).
General procedure C, from 2-(3,5-dimethyl-1H-pyrazol-1-yl)-
4,6-dimethoxypyrimidine (15) (47 mg, 0.20 mmol) with 6
equiv of LiCl and microwave irradiation at 160 °C for 3 h to
give 21 as white solid (10 mg, 24%): mp 197−199 °C; 1H
NMR (CDCl3, 500 MHz) δ: 6.06 (s, 1H, Ar H), 5.58 (s, 1H,
Ar H), 2.66 (s, 3H, CH3), 2.26 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 152.8 (C), 148.0 (C), 143.8 (C), 112.0
(CH), 87.2 (CH), 15.0 (CH3), 13.6 (CH3); MS (ESI) m/z
207 [M + H]+; HRMS (ESI) m/z: calcd for C9H21N4O2
+ [M +
H]+, 207.0877; found, 207.0878.
5-Chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-ol
(22). General procedure C, from 5-chloro-2-(3,5-dimethyl-1H-
pyrazol-1-yl)-4-methoxypyrimidine (16) (33 mg, 0.14 mmol)
to give 22 as white solid (38 mg, 86%): mp 151−152 °C; 1H
NMR (CDCl3, 500 MHz) δ: 10.76 (s(b), 1H, OH), 8.00 (s,
1H, Ar H), 6.08 (s, 1H, Ar H), 2.66 (s, 3H, CH3), 2.27 (s, 3H,
CH3);
13C NMR (CDCl3, 125 MHz) δ: 157.3 (C), 152.6
(CH), 151.0 (C), 147.0 (C), 143.8 (C), 119.3 (C), 112.0
(CH), 14.9 (CH3), 13.6 (CH3); MS (ESI) m/z 225 [M + H]
+
(35Cl); 227 [M + H]+ (37Cl); HRMS (ESI) m/z: calcd for
C9H10N4OCl
+ [M + H]+, 225.0538; found, 225.0536.
General Procedure D for the Formation of Substituted
Amides (Compounds 23−25). Methyl 2-(3,5-dimethyl-1H-
pyrazol-1-yl)-6-methylpyrimidine-4-carboxylate (17) (1 equiv)
was dissolved in suitable amines (5 equiv) in methanol, and
the reaction mixture was left to stir overnight at rt. The
reaction mixture was concentrated in vacuo to give the
intended product.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidine-4-
carboxamide (23). General procedure D, using 7 M NH3 in
methanol (1.54 mL) to give 23 as oﬀ-yellow solid (493 mg,
99%): 1H NMR (CDCl3, 500 MHz) δ: 7.85 (s, 1H, Ar H),
7.79 (s(b), 1H, NH), 6.10 (s, 1H, Ar H), 6.00 (s(b), 1H, NH),
2.72 (s, 3H, CH3), 2.70 (s, 3H, CH3), 2.37 (s, 3H, CH3);
13C
NMR (CDCl3, 125 MHz) δ: 172.4 (C), 164.9 (C), 157.1 (C),
156.6 (C), 151.9 (C), 142.7 (C), 115.0 (CH), 110.8 (CH),
24.8 (CH3), 15.5 (CH3), 13.9 (CH3); MS (ESI) m/z 232 [M
+ H]+; HRMS (ESI) m/z: calcd for C11H14N5O
+ [M + H]+,
232.1193; found, 232.1212.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-N,6-dimethylpyrimi-
dine-4-carboxamide (24). General procedure D, using 2 M
methylamine in methanol (1.29 mL) to give 24 as yellow solid
(126 mg, 100%): 1H NMR (CDCl3, 500 MHz) δ: 8.24 (s(b),
1H, NH), 7.84 (s, 1H, Ar H), 6.09 (s, 1H, Ar H), 3.06 (d, J =
5.1 Hz, 3H, NCH3), 2.70 (s, 3H, CH3), 2.69 (s, 3H, CH3),
2.37 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ: 171.9
(C), 163.3 (C), 157.9 (C), 156.4 (C), 151.7 (C), 143.0 (C),
114.7 (CH), 110.6 (CH), 26.3 (CH3), 24.6 (CH3), 15.5
(CH3), 13.8 (CH3); MS (ESI) m/z 246 [M + H]
+; HRMS
(ESI) m/z: calcd for C12H16N5O
+ [M + H]+, 246.1349; found,
246.1374.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-N,N,6-trimethylpyrimi-
dine-4-carboxamide (25). General procedure D, using 2 M
dimethylamine in methanol (1.34 mL) to give 25 as oﬀ-yellow
solid (138 mg, 99%): 1H NMR (CDCl3, 500 MHz) δ: 7.18 (s,
1H, Ar H), 5.97 (s, 1H, Ar H), 3.06 (s, 3H, NCH3), 3.02 (s,
3H, NCH3), 2.58 (s, 3H, CH3), 2.56 (s, 3H, CH3), 2.27 (s,
3H, CH3);
13C NMR (CDCl3, 125 MHz) δ: 171.3 (C), 166.7
(C), 162.3 (C), 156.4 (C), 151.7 (C), 143.0 (C), 116.0 (CH),
110.5 (CH), 38.7 (CH3), 35.5 (CH3), 24.7 (CH3), 15.4
(CH3), 14.0 (CH3); MS (ESI) m/z 260 [M + H]
+; HRMS
(ESI) m/z: calcd for C13H18N5O
+ [M + H]+, 260.1506; found,
260.1510.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidine-4-
carbonitrile (26). To a solution of 2-(3,5-dimethyl-1H-pyrazol-
1-yl)-6-methylpyrimidine-4-carboxamide (23) (50 mg, 0.22
mmol) in THF (1 mL) was added Burgess reagent (258 mg,
1.08 mmol) in two portions, and the reaction mixture was
allowed to stir overnight at rt. Water was added to the reaction,
and the reaction mixture was washed with DCM. The organic
phase was separated, dried, and concentrated in vacuo to give a
residue, which was puriﬁed using ﬂash column chromatog-
raphy (0−50% ethyl acetate in heptane) to give 26 as a white
solid (43 mg, 93%): 1H NMR (CDCl3, 500 MHz) δ: 7.34 (s,
1H, Ar H), 6.10 (s, 1H, Ar H), 2.72 (s, 3H, CH3), 2.69 (s, 3H,
CH3), 2.37 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ:
172.3 (C), 157.5 (C), 152.8 (C), 143.9 (C), 141.6 (C), 120.2
(CH), 115.3 (C), 111.5 (CH), 24.7 (CH3), 15.6 (CH3), 14.0
(CH3); MS (ESI) m/z 214 [M + H]
+; HRMS (ESI) m/z:
calcd for C11H12N5
+ [M + H]+, 214.1087; found, 214.1101.
Ethyl 2-Methyl-3-oxopropanoate (27). To a stirred
solution of ethyl propionate (2.30 mL, 2.04 g, 20 mmol),
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methyl formate (3.70 mL, 3.60 g, 60 mmol) in DCM (20 mL)
at 0 °C was added 1.0 M TiCl4 solution in DCM dropwise (40
mL). After 30 min, trimethylamine (6.97 mL, 5.06 g, 50
mmol) was added dropwise. After 1 h, the reaction mixture
was warmed to rt over the period of 3 h. The reaction was then
quenched with water and extracted with DCM. The organic
phase was then separated, dried, and concentrated in vacuo to
give a residue, which was puriﬁed using ﬂash column
chromatography (DCM) to give 27 as oil with fruity odor
(1.63 g, 63%). NMR spectra indicated a mixture of the
aldehyde and enol tautomers with the ratio of approximately
1.5:1. 1H NMR (CDCl3, 500 MHz) δ: Aldehyde tautomer:
9.81 (d, J = 1.5 Hz, 1H, aldehyde H), 4.27 (q, J = 7.2 Hz, 2H,
CH2CH3), 3.41 (qd, J1 = 7.2 Hz, J2 = 1.5 Hz, 1H, CH), 1.38
(d, J = 7.2 Hz, 3H, CH3), 1.33 (t, J = 7.2 Hz, 3H, CH2CH3).
Enol tautomer: 11.3 (d, J = 12.5 Hz, 1H, OH), 7.02 (dq, J1 =
12.5 Hz, J2 = 1.2 Hz, 1H, CH), 4.27 (q, J = 7.2 Hz, 2H,
CH2CH3), 1.70 (d, J = 1.2 Hz, 3H, CH3), 1.35 (t, J = 7.1 Hz,
3H, CH2CH3).
13C NMR (CDCl3, 125 MHz) δ: Aldehyde
tautomer: 197.4 (CH), 169.7 [C, estimated from hetero-
nuclear multiple bond correlation (HMBC)], 61.6 (CH2), 52.7
(CH), 14.2 (CH3), 10.3 (CH3). Enol tautomer: 172.4 (C,
estimated from HMBC), 160.1 (CH), 100.2 (C), 60.4 (CH2),
14.2 (CH3), 12.4 (CH3). NMR spectra in concordance with
those reported by El-Mansy et al.50
General Procedure E for the Formation of Pyrazolone
Derivatives (Compounds 28 and 29). To a solution of
aminoguanidine hemisulfate (1 equiv) in water (2.5 M) were
added NaOAc (1 equiv) and the appropriate β-keto ester or β-
aldehydoester (1 equiv). The reaction mixture was left to stir at
rt. The precipitate was then ﬁltered and washed with minimum
volume of cold water to give the intended product.
5-Hydroxy-3-methyl-1H-pyrazole-1-carboximidamide
(28). General procedure E, using ethyl acetoacetate (5.46 mL,
5.61 g, 43.1 mmol) and stirred overnight to give 28 as an oﬀ-
white solid (3.87 g, 64%): 1H NMR (DMSO-d6, 500 MHz) δ:
10.3 (s(b), 1H, OH), 7.72 (s(b), 3H, NH2 and NH), 4.43 (s,
1H, Ar H), 1.97 (s, 3H, CH3);
13C NMR (DMSO-d6, 125
MHz) δ: 168.1 (C), 156.5 (C), 153.5 (C), 82.6 (CH), 15.4
(CH3); HRMS (ESI) m/z: calcd for C5H9N4O
+ [M + H]+,
141.0771; found, 141.0757.
5-Hydroxy-4-methyl-1H-pyrazole-1-carboximidamide
(29). General procedure E, using ethyl 2-methyl-3-oxopropa-
noate (27) (381 mg, 2.93 mmol) and stirred for 7 days to give
29 as as oﬀ-white solid (214 mg, 52%): 1H NMR (DMSO-d6,
500 MHz) δ: 10.5 (s(b), 1H, OH), 7.83 (s(b), 3H, NH2 and
NH), 7.28 (s, 1H, Ar H), 1.64 (s, 3H, CH3);
13C NMR
(DMSO-d6, 125 MHz) δ: 165.8 (C), 154.0 (C), 148.5 (CH),
88.8 (C), 8.0 (CH3); HRMS (ESI) m/z: calcd for C5H9N4O
+
[M + H]+, 141.0771; found, 141.0775.
General Procedure F for the Formation of Carboximida-
mides (Compounds 32−34). To a solution of appropriate
amine (1.01 equiv) in acetonitrile (2.3 M) were added
triethylamine (1.01 equiv) and 1H-pyrazole-1-carboximida-
mide (1 equiv). The reaction mixture was reﬂuxed overnight.
The reaction mixture was then cooled down to rt, and the
precipitate was ﬁltered from the reaction mixture to give the
product as a hydrochloride salt.
Pyrrolidine-1-carboximidamide Hydrochloride (32). Gen-
eral procedure F, using pyrrolidine (132 μL, 113 mg, 1.58
mmol) to give 32 as a light yellow solid (177 mg, 75%): 1H
NMR (DMSO-d6, 500 MHz) δ: 7.35 (s(b), 4× NH), 3.34−
3.31 (m, 4H, 2× CH2), 1.92−1.89 (m, 4H, 2× CH2); 13C
NMR (DMSO-d6, 125 MHz) δ: 155.1 (C), 47.4 (2× CH2),
25.2 (2× CH2); HRMS (ESI) m/z: calcd for C5H12N3
+ [M +
H]+, 114.1026; found, 114.1042.
2-Methylpyrrolidine-1-carboximidamide Hydrochloride
(33). General procedure F, using 2-methylpyrrolidine (530
μL, 442 mg, 5.19 mmol) to give 33 as a light yellow solid (717
mg, 85%): 1H NMR (DMSO-d6, 500 MHz) δ: 7.35 (s(b), 4×
NH), 4.09−4.03 (m, 1H, CH), 3.47−3.43 (m, 1H, CH from
CH2), 3.28−3.23 (m, 1H, CH from CH2), 2.06−1.88 (m, 3H,
CH2 and CH from CH2), 1.69−1.62 (m, 1H, CH from CH2),
1.10 (d, J = 6.3 Hz, 3H, CH3);
13C NMR (DMSO-d6, 125
MHz) δ: 154.6 (C), 53.9 (CH), 47.3 (CH2), 32.5 (CH2), 22.8
(CH2), 19.2 (CH3); HRMS (ESI) m/z: calcd for C6H14N3
+
[M + H]+, 128.1182; found, 128.1193.
Morpholine-4-carboximidamide Hydrochloride (34). Gen-
eral procedure F, using morpholine (451 μL, 456 mg, 5.23
mmol) to give 34 as a light yellow solid (633 mg, 74%): 1H
NMR (DMSO-d6, 500 MHz) δ: 7.66 (s(b), 4× NH), 3.65−
3.63 (m, 4H, 2× CH2), 3.44−3.42 (m, 4H, 2× CH2); 13C
NMR (DMSO-d6, 125 MHz) δ: 157.1 (C), 65.7 (2× CH2),
45.6 (2× CH2); HRMS (ESI) m/z: calcd for C5H12N3O
+ [M +
H]+, 130.0975; found, 130.0975.
General Procedure G for the Ring Formation of
Substituted Pyrimidines from Carboximidamides (Com-
pounds 30, 31, 33, 36, and 37). To a solution of the suitable
carboximidamides (1 equiv) in ethanol (0.6 M) were added
NaOEt (1 equiv) and ethyl acetoacetate (1 equiv). The
reaction mixture was reﬂuxed overnight. Work-up and
puriﬁcation described individually in each example gave the
intended product.
2-(5-Hydroxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimi-
din-4-ol (30). General procedure G, from 5-hydroxy-3-methyl-
1H-pyrazole-1-carboximidamide (28) (315 mg, 2.25 mmol).
The precipitate was ﬁltered and washed with a minimal volume
of cold acetonitrile to give 30 as a oﬀ-red solid (174 mg, 38%):
1H NMR (DMSO-d6, 500 MHz) δ: 15.0 (s(b), 1H, OH), 5.70
(s, 1H, Ar H), 4.50 (s, 1H, Ar H), 2.13 (s, 3H, CH3), 1.98 (s,
3H, CH3);
13C NMR (DMSO-d6, 125 MHz) δ: 168.0 (C),
165.4 (C), 162.1 (C), 154.0 (C), 151.7 (C), 105.5 (CH), 83.0
(CH), 24.2 (CH3), 15.4 (CH3); MS (ESI) m/z 207 [M + H]
+;
HRMS (ESI) m/z: calcd for C9H11N4O2
+ [M + H]+, 207.0877;
found, 207.0899.
2-(5-Hydroxy-4-methyl-1H-pyrazol-1-yl)-6-methylpyrimi-
din-4-ol (31). General procedure G, from 5-hydroxy-4-methyl-
1H-pyrazole-1-carboximidamide (29) (98 mg, 0.70 mmol).
The reaction mixture was concentrated in vacuo, and the
residue was puriﬁed using mass-directed HPLC to give 31 as
an oﬀ-yellow solid (41 mg, 28%): 1H NMR (CDCl3, 500
MHz) δ: 9.19 (s(b), 2H, 2× OH), 7.32 (s, 1H, Ar H), 5.98 (s,
1H, Ar H), 2.21 (s, 3H, CH3), 1.85 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 162.4 (C), 161.3 (C), 148.8 (C), 144.8
(C), 132.5 (CH), 109.0 (CH), 98.9 (C), 23.3 (CH3), 6.5
(CH3); MS (ESI) m/z 207 [M + H]
+; HRMS (ESI) m/z:
calcd for C9H11N4O2
+ [M + H]+, 207.0877; found, 207.0888.
6-Methyl-2-(pyrrolidin-1-yl)pyrimidin-4-ol (35). General
procedure G, from pyrrolidine-1-carboximidamide hydro-
chloride (32) (173 mg, 1.16 mmol). Water was added to the
reaction, and the mixture was washed with DCM. The organic
phase was then separated, dried, and concentrated in vacuo to
give a residue, which was puriﬁed using ﬂash column
chromatography (0−5% MeOH/NH3 in DCM) to give 35
as an oﬀ-white solid (133 mg, 64%): 1H NMR (CDCl3, 500
MHz) δ: 11.2 (s(b), 1H, OH), 5.61 (s, 1H, Ar H), 3.60−3.58
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(m, 4H, 2× CH2), 2.18 (s, 3H, CH3), 2.03−2.00 (m, 4H, 2×
CH2);
13C NMR (CDCl3, 125 MHz) δ: 167.8 (C), 165.8 (C),
152.3 (C), 99.5 (CH), 46.8 (2× CH2), 25.4 (2× CH2), 24.5
(CH3); MS (ESI) m/z 180 [M + H]
+; HRMS (ESI) m/z:
calcd for C9H13N3O
+ [M + H]+, 180.1131; found, 180.1136.
6-Methyl-2-(2-methylpyrrolidin-1-yl)pyrimidin-4-ol (36).
General procedure G, from 2-methylpyrrolidine-1-carboximi-
damide hydrochloride (33) (195 mg, 1.19 mmol). Water was
added to the reaction, and the mixture was washed with DCM.
The organic phase was then separated, dried, and concentrated
in vacuo to give a residue, which was puriﬁed using ﬂash
column chromatography (0−5% MeOH/NH3 in DCM) to
give 36 as a light brown solid (167 mg, 72%): 1H NMR
(CDCl3, 500 MHz) δ: 11.0 (s(b), 1H, OH), 5.60 (s, 1H, Ar
H), 4.40−4.34 (m, 1H, CH), 3.72−3.67 (m, 1H, CH from
CH2), 3.50−3.45 (m, 1H, CH from CH2), 2.17 (s, 3H, CH3),
2.14−1.97 (m, 2H, 2× CH from CH2), 1.75−1.70 (m, 1H, CH
from CH2), 1.24 (d, J = 6.3 Hz, 3H, CH3);
13C NMR (CDCl3,
125 MHz) δ: 167.8 (C), 165.9 (C), 151.9 (C), 99.3 (CH),
53.6 (CH), 46.8 (CH2), 32.6 (CH2), 24.6 (CH3), 23.2 (CH2),
19.4 (CH3); MS (ESI) m/z 194 [M + H]
+; HRMS (ESI) m/z:
calcd for C10H15N3O
+ [M + H]+, 194.1288; found, 194.1309.
6-Methyl-2-morpholinopyrimidin-4-ol (37). General pro-
cedure G, from morpholine-4-carboximidamide hydrochloride
(34) (97 mg, 0.59 mmol). Water was added to the reaction,
and the mixture was washed with DCM. The organic phase
was then separated, dried, and concentrated in vacuo to give a
residue, which was puriﬁed using ﬂash column chromatog-
raphy (0−5% MeOH/NH3 in DCM) to give 37 as an oﬀ-white
solid (59 mg, 52%): 1H NMR (CDCl3, 500 MHz) δ: 12.0
(s(b), 1H, OH), 5.66 (s, 1H, Ar H), 3.81−3.79 (m, 4H, 2×
CH2), 3.76−3.74 (m, 4H, 2× CH2), 2.18 (s, 3H, CH3); 13C
NMR (CDCl3, 125 MHz) δ: 167.7 (C), 166.2 (C), 153.8 (C),
100.8 (CH), 53.6 (CH), 66.5 (2× CH2), 44.8 (2× CH2), 24.4
(CH3); MS (ESI) m/z 196 [M + H]
+; HRMS (ESI) m/z:
calcd for C9H14N3O2
+ [M + H]+, 196.1081; found, 196.1094.
General Procedure H for the Formation of 5-Substituted
Pyrimidine Analogues (Compounds 38, 39, and 42). To a
solution of 3,5-dimethyl-1H-pyrazole-1-carboximidamide ni-
trate (1 equiv) in ethanol (0.65 M) were added the appropriate
1,3-dicarbonyls or acrylates (1.1 equiv) and NaOH (1.1
equiv). The reaction mixture was stirred overnight at 100 °C.
Work-up and puriﬁcation described individually in each
example gave the intended product.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-5-methylpyrimidin-4-ol
(38). General procedure H, using ethyl 2-methyl-3-oxopropa-
noate (27) (260 mg, 2.00 mmol). The reaction mixture was
then cooled down to rt and concentrated in vacuo to give a
residue, which was then puriﬁed with mass-directed HPLC to
give 38 as a white solid (77 mg, 19%): 1H NMR (CDCl3, 500
MHz) δ: 10.6 (s(b), 1H, OH), 7.70 (s, 1H, Ar H), 6.04 (s, 1H,
Ar H), 2.66 (s, 3H, CH3), 2.26 (s, 3H, CH3), 2.09 (s, 3H,
CH3);
13C NMR (CDCl3, 125 MHz) δ: 162.0 (C), 151.6 (C),
150.5 (CH), 146.8 (C), 143.3 (C), 121.0 (C), 111.2 (CH),
14.9 (CH3), 13.6 (CH3), 12.8 (CH3); MS (ESI) m/z 216 [M
+ H]+; HRMS (ESI) m/z: calcd for C10H13N4O
+ [M + H]+,
205.1084; found, 205.1111.
Ethyl 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-hydroxypyrimi-
dine-5-carboxylate (39). General procedure H, using diethyl
2-(ethoxymethylene)malonate (2.00 mL, 2.14 g, 9.89 mmol).
The reaction mixture was then cooled down to rt, and the
precipitate was ﬁltered and washed with a minimal volume of
cold ethanol to give 39 as a white solid (1.17 g, 50%): 1H
NMR (D2O, 500 MHz) δ: 8.64 (s, 1H, Ar H), 6.09 (s, 1H, Ar
H), 4.28 (q, J = 7.1 Hz, 2H, CH2), 2.45 (s, 3H, CH3), 2.18 (s,
3H, CH3), 1.30 (t, J = 7.2 Hz, 3H, CH3);
13C NMR (D2O, 125
MHz) δ: 172.5 (C), 168.1 (C), 160.1 (C), 158.2 (CH), 151.7
(C), 143.4 (C), 110.4 (C), 109.1 (CH), 61.6 (CH2), 13.5
(CH3), 12.8 (CH3), 12.4 (CH3); MS (ESI) m/z 263 [M +
H]+; HRMS (ESI) m/z: calcd for C12H15N4O3
+ [M + H]+,
263.1139; found, 263.1161.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-hydroxypyrimidine-5-
carbonitrile (42). General procedure H, using ethyl 2-cyano-3-
ethoxyacrylate (433 mg, 2.56 mmol). The reaction mixture was
then cooled down to rt, and the precipitate was ﬁltered and
washed with a minimal volume of cold ethanol. The precipitate
was then redissolved in methanol and the solution was passed
through an ion exchange column to remove any side products
and give 42 as an oﬀ-white solid (142 mg, 28%): 1H NMR
(CDCl3, 500 MHz) δ: 10.9 (s(b), 1H, OH), 8.31 (s, 1H, Ar
H), 6.15 (s, 1H, Ar H), 2.68 (s, 3H, CH3), 2.30 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ: 162.1 (CH), 157.5 (C),
154.7 (C), 150.5 (C), 145.0 (C), 113.6 (C), 113.4 (CH), 15.2
(CH3), 13.7 (CH3); MS (ESI) m/z 216 [M + H]
+; HRMS
(ESI) m/z: calcd for C10H10N5O
+ [M + H]+, 216.0880; found,
216.0900.
Alternative Procedure Using Burgess Reagent. To a
solution of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-hydroxypyrimi-
dine-5-carboxamide (41) (112 mg, 0.48 mmol) in THF (1
mL) was added Burgess reagent (286 mg, 1.20 mmol). The
reaction mixture was stirred overnight at rt. The reaction
mixture was concentrated in vacuo, and the residue was
puriﬁed using mass-directed HPLC to give 42 as a white solid
(21 mg, 20%).
Methyl 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-hydroxypyri-
midine-5-carboxylate (40). To a solution of ethyl 2-(3,5-
dimethyl-1H-pyrazol-1-yl)-4-hydroxypyrimidine-5-carboxylate
(39) (130 mg, 0.50 mmol) in methanol (2.5 mL) was added 7
M NH3 in methanol (354 μL). The reaction mixture was
stirred overnight at 75 °C. The reaction mixture was then
concentrated in vacuo to give 40 as a white solid (125 mg,
102%): 1H NMR (D2O, 500 MHz) δ: 8.64 (s, 1H, Ar H), 6.09
(s, 1H, Ar H), 3.80 (s. 3H, CH3), 2.42 (s, 3H, CH3), 2.18 (s,
3H, CH3);
13C NMR (D2O, 125 MHz) δ: 172.7 (C), 168.6
(C), 161.0 (CH), 158.4 (CH), 151.7 (C), 143.4 (C), 110.1
(C), 109.1 (CH), 52.0 (CH3), 12.8 (CH3), 12.4 (CH3); MS
(ESI) m/z 249 [M + H]+; HRMS (ESI) m/z: calcd for
C11H13N4O3
+ [M + H]+, 249.0982; found, 249.0998.
2-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-hydroxypyrimidine-5-
carboxamide (41). Ethyl 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-
hydroxypyrimidine-5-carboxylate (39) (183 mg, 0.70 mmol)
was suspended in NH4OH (3 mL). The suspension was then
stirred at 75 °C overnight, of which the suspension became
clear. The reaction mixture was then cooled to rt and was
concentrated in vacuo to give 41 as a white solid (140 mg,
86%): 1H NMR (MeOD, 500 MHz) δ: 8.77 (s, 1H, Ar H),
6.04 (s, 1H, Ar H), 2.60 (s, 3H, CH3), 2.24 (s, 3H, CH3);
13C
NMR (D2O, 125 MHz) δ: 174.4 (C), 170.7 (C), 159.8 (CH),
159.5 (C), 151.5 (C), 144.2 (C), 111.9 (C), 110.2 (CH), 14.7
(CH3), 13.5 (CH3); MS (ESI) m/z 234 [M + H]
+; HRMS
(ESI) m/z: calcd for C10H12N5O2
+ [M + H]+, 234.0986;
found, 234.0996.
General Procedure I for the Coupling of Chloropyridines
and 3,5-Dimethylpyrazoles (Compounds 43 and 44). To a
solution of appropriate chloropyridine (1 equiv) in acetonitrile
(0.6 M) were added 3,5-dimethylpyrazole (1 equiv), KOH (1
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equiv), and 18-crown-6 (0.1 equiv). The reaction mixture was
subjected to microwave irradiation at 80 °C. The reaction
mixture was quenched with 2 M HCl, and the aqueous layer
was extracted with ethyl acetate. The organic layer was then
separated and concentrated in vacuo to give the residue, which
was then puriﬁed using ﬂash column chromatography (0−10%
EtOAc in heptane) to give the intended product.
2-Chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-4-methylpyri-
dine (43). General procedure I, from 2,6-dichloro-4-methyl-
pyridine (486 mg, 3.0 mmol), and subjected to microwave
irradiation for 1.25 h. Chromatographic puriﬁcation gave
compound 43 as a white solid (331 mg, 50%): mp 45−46 °C;
1H NMR (CDCl3, 500 MHz) δ: 7.65 (s, 1H, Ar H), 7.01 (s,
1H, Ar H), 6.00 (s, 1H, Ar H), 2.67 (s, 3H, CH3), 2.41 (s, 3H,
CH3), 2.31 (s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ:
152.9 (C), 152.5 (C), 150.3 (C), 148.7 (C), 142.2 (C), 121.3
(CH), 114.0 (CH), 109.5 (CH), 21.0 (CH3), 14.7 (CH3),
13.6 (CH3); MS (ESI) m/z 222 [M + H]
+; HRMS (ESI) m/z:
calcd for C11H13N3Cl
+ [M + H]+, 222.0793; found, 222.0803.
2-Chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridine (44).
General procedure I, from 2,6-dichloropyridine (444 mg, 3.0
mmol), and subjected to microwave irradiation for 2.25 h.
Chromatographic puriﬁcation gave compound 44 as a white
solid (345 mg, 55%): mp 68−69 °C; 1H NMR (CDCl3, 500
MHz) δ: 7.83 (d, J = 8.1 Hz, 1H, Ar H), 7.73 (dd, J1 = 7.9 Hz,
J2 = 7.9 Hz, 1H, Ar H), 7.16 (d, J = 7.7 Hz, 1H, Ar H), 6.01 (s,
1H, Ar H), 2.69 (s, 3H, CH3), 2.31 (s, 3H, CH3);
13C NMR
(CDCl3, 125 MHz) δ: 153.1 (C), 150.5 (C), 148.7 (C), 142.2
(C), 140.5 (CH), 120.3 (CH), 113.2 (CH), 109.7 (CH), 14.8
(CH3), 13.6 (CH3); MS (ESI) m/z 208 [M + H]
+; HRMS
(ESI) m/z: calcd for C10H11N3Cl
+ [M + H]+, 208.0636; found,
208.0642.
General Procedure J for the Copper-Catalyzed Hydrox-
ylation of Aryl Halides (Compounds 45 and 46). To a
solution of the suitable aryl halide (1.0 equiv) in water (0.06
M) were added 55% tetrabutylammonium hydroxide (4.0
equiv), CuI (0.1 equiv), and 8-hydroxyquinoline 1-oxide (0.4
equiv). The reaction mixture was then subjected to microwave
irradiation at 180 °C for 3 h. The reaction mixture was washed
with ethyl acetate, and the organic phase was separated, dried,
and concentrated in vacuo to give a residue, which was puriﬁed
using ﬂash column chromatography (0−25% EtOAc in
heptane) to give the desired product.
6-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-methylpyridin-2-ol
(45). General procedure J, from 2-chloro-6-(3,5-dimethyl-1H-
pyrazol-1-yl)-4-methylpyridine (43) (100 mg, 0.45 mmol) to
give compound 45 as white solid (53 mg, 58%): mp 132−134
°C; 1H NMR (CDCl3, 500 MHz) δ: 9.52 (s(b), 1H, OH),
6.33 (s, 1H, Ar H), 6.31 (s, 1H, Ar H), 6.02 (s, 1H, Ar H),
2.50 (s, 3H, CH3), 2.30 (s, 3H, CH3), 2.27 (s, 3H, CH3);
13C
NMR (CDCl3, 125 MHz) δ: 162.2 (C), 153.1 (C), 150.5 (C),
142.9 (C), 140.4 (C), 113.1 (CH), 109.9 (CH), 100.1 (CH),
21.9 (CH3), 13.8 (CH3), 13.5 (CH3); MS (ESI) m/z 204 [M
+ H]+; HRMS (ESI) m/z: calcd for C11H14N3O
+ [M + H]+,
204.1131; found, 204.1148.
6-(3,5-Dimethyl-1H-pyrazol-1-yl)pyridin-2-ol (46). General
procedure J, from 2-chloro-6-(3,5-dimethyl-1H-pyrazol-1-yl)-
pyridine (44) (42 mg, 0.20 mmol) to give compound 46 as oﬀ-
white solid (33 mg, 87%): mp 107−108 °C; 1H NMR (CDCl3,
500 MHz) δ: 9.83 (s(b), 1H, OH), 7.52 (dd, J1 = 8.9 Hz, J2 =
7.6 Hz, 1H, Ar H), 6.49 (d, J = 8.7 Hz, 1H, Ar H), 6.47 (d, J =
7.2 Hz, 1H, Ar H), 6.03 (s, 1H, Ar H), 2.50 (s, 3H, CH3), 2.27
(s, 3H, CH3);
13C NMR (CDCl3, 125 MHz) δ: 162.2 (C),
150.7 (C), 143.4 (C), 141.3 (CH), 140.5 (C), 113.9 (CH),
110.2 (CH), 97.5 (CH), 13.9 (CH3), 13.5 (CH3); MS (ESI)
m/z 190 [M + H]+; HRMS (ESI) m/z: calcd for C10H12N3O
+
[M + H]+, 190.0975; found, 190.0966.
Metabolomics. General. Compounds tested were ob-
tained from commercial suppliers (marketed antibiotics) or in-
house (hit compounds and analogues). S. aureus RN6390 was
from in-house laboratory collection. LB were prepared in-
house. All procedures were performed under aseptic
conditions.
Determination of MIC via Microdilution Method. A series
of dilution was prepared from a stock solution of compounds
(dissolved in water/DMSO for known antibacterial drugs,
DMSO for other synthetic in-house compounds) by diluting
the stock solution with LB media. From each dilution, 100 μL
was added into the wells of a 96-well plate. At the same time,
the inoculum was prepared by making a 0.5 McFarland
standard culture by diluting an overnight culture of S. aureus
RN6390 with the appropriate media. The standard culture was
then further diluted 100-fold with the same media. This diluted
culture (100 μL) was added into the wells of a 96-well plate,
bringing the ﬁnal volume to 200 μL. The plate was covered
with the lid provided and was incubated at 35−37 °C in air for
18−20 h. The MIC of the compound (averaged from two
independent replicates) was deﬁned as the lowest concen-
tration of the compound, at which there was no visible growth.
Metabolomics Study of S. aureus RN6390 upon Exposure
to Various Compounds with Antibacterial Activity. The
metabolite extraction was adapted from Vincent et al.17 Brieﬂy,
a 0.5 mL overnight culture of S. aureus RN6390 was inoculated
into 49.5 mL of LB and the culture was incubated with shaking
at 200 rpm at 37 °C. At 2 h, antibacterial compounds were
added at 4× MIC. Samples were taken at 0, 1.5, and 3 h after
the addition in 10 mL aliquots. Samples were cooled to 4 °C in
a dry-ice-ethanol bath to quench metabolism before they were
temporarily stored in ice. Cells (10 mL) were pelleted at 3894
relative centrifugal force (RCF), washed in 10 mL of cold
0.85% saline, and then resuspended in 1 mL of 0.85% saline.
The OD600nm of the cell suspension was taken and adjusted to
1. A 1 mL aliquot of cells was pelleted and resuspended in 200
μL of chloroform−methanol−water mixture (1:3:1, by
volume) in a microcentrifuge tube. Acid-washed glass beads
(200 μL) with the particle size ≤106 μm (Sigma-Aldrich) were
added to the suspension, and the tube was shaken at 2000 rpm
at 4 °C for 45 min (Eppendorf ThermoMixer C). The tube
was subjected to a ﬁnal centrifugation at 15871 RCF of which
the supernatant was then taken and kept at −80 °C prior to
data acquisition. Nine independent samples were generated for
the untreated control, and three independent samples were
generated for each treatment group. The data acquisition was
similar to Vincent et al.17 A 10 μL aliquot of each sample was
run in a randomized order on a ZIC-pHILIC (polymeric
hydrophilic interaction chromatography) column (Merck
SeQuant) coupled to an Orbitrap mass spectrometer (Thermo
Scientiﬁc) according to previously published methods.51 Data
analysis was performed using the MzMatch52 and IDEOM53
software packages for untargeted, initial analyses. PiMP54 was
used for further pathway analysis, generating log2 fold changes
and peak veriﬁcation. The PCA plot was generated using the
MetaboAnalyst software.47 Metabolomics data have been
deposited to the EMBL-EBI MetaboLights database (DOI:
10.1093/nar/gks1004. PubMed PMID: 23109552) with the
identiﬁer MTBLS788.
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